Is CEL-SCI Corporation (CVM) a good investment?
CEL-SCI Corporation (CVM) currently trades at $11.62 and has fallen by 2.02% today. CVM went down $0.24 from the previous closing price of $11.86. The high forecast for CEL-SCI Corporation is $19.00 and the low is $18.00. The company’s market cap is $433.54 million with a 52 week high of $17.80 and a 52 week low of $3.70. CVM has changed in price by 5.84 per share in the last 12 months. As the 9-year phase III trial is finally coming to an end, LEAPS funding could come soon for COVID-19 treatment.
CEL-SCI Corporation has a weak EPS of -0.88. This means the company lost $-0.88 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article.
About CEL-SCI Corporation:
CEL-SCI Corporation (NYSE American: CVM), a biotechnology company, is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases. Use your immune system to fight disease. That’s the root of CEL-SCI’s mission.